FDA clears Cervarix for 10- to 25-year-old females

10/18/2009 | WebMD

GlaxoSmithKline has won FDA approval for the use of human papillomavirus vaccine Cervarix in girls ages 10 to 25. The decision is based on clinical trials that demonstrated that Cervarix was 93% effective in protecting patients in the age group from cervical precancers associated with HPV 16 or HPV 18 strains.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX